Anti-Mouse CD209b [Clone 22D1] — Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse CD209b [Clone 22D1] — Purified in vivo PLATINUM™ Functional Grade
Product No.: C6859
Clone 22D1 Target CD209b Formats AvailableView All Product Type Monoclonal Antibody Alternate Names DC-SIGNR1 Isotype Armenian Hamster IgG1 κ Applications B , FC , IHC FF , in vivo , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Armenian Hamster Recommended Isotype Controls Recommended Dilution Buffer Immunogen Purified Recombinant Mouse CD209b (C-terminal peptide) Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2829823 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 22D1 recognizes an epitope on mouse CD209b. Background CD209b has a molecular weight of 37 kD and is a single-pass type II membrane protein containing a C-type lectin domain. CD209b plays a role in innate immune response, mediating the recognition and uptake of pathogen products such as lipopolysaccharides, pneumococcal polysaccharides, and dextrans. CD209b is a mouse homolog of human CD209, also known as DC-SIGN. Both primates and mice have several paralogs of CD209 that, within the species, are more comparable to each other than to orthologs of other species. Although DC-SIGN expression is similar in function and dendritic expression in both mice and humans, they are not unique orthologs. Higher primates have at least three DC-SIGN genes (DC-SIGN, DC-SIGNL1 and DC-SIGNL2); although DC-SIGNL2 has not been detected in humans. Up to eight paralogs of DC-SIGN have been reported in some laboratory mouse strains, some of which are differentially expressed on different cell types. On macrophages, DC-SIGN activates phagocytosis via the recognition and binding of mannose type carbohydrates, a class of pathogen associated molecular patterns (PAMPs) frequently found on viruses, bacteria and fungi. On myeloid and pre-plasmacytoid dendritic cells, DC-SIGN initiates immune response via the recognition of pathogen haptens (which elicits the production of antibodies), in addition to the mediation of dendritic cell rolling interactions with blood endothelium and activation of CD4+ T cells. Furthermore, DC-SIGN functions as receptor for viruses such as HIV and Hepatitis C. DC-SIGN, in conjunction with other C-type lectins, also plays a role in the recognition of tumors via dendritic cells. Hence, the therapeutic potential for DC-SIGN as a target for dendritic cell based cancer vaccine. Antigen Distribution CD209b is predominantly expressed on macrophages in the spleen marginal zone and lymph nodes medulla. Ligand/Receptor CD209B binds to microbial polysaccharides and is a receptor for ICAM-3. Function CD209B is a C-type lectin receptor, mediating the recognition of various bacteria and viruses during innate immue response. NCBI Gene Bank ID UniProt.org Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone 22D1 is an anti-mouse CD209b (SIGN-R1) monoclonal antibody widely used in various in vivo mouse studies. This Armenian hamster IgG antibody specifically targets SIGN-R1, a type II transmembrane C-type lectin receptor that plays important roles in innate immunity. Primary In Vivo ApplicationsTemporary Knockdown of SIGNR1 Expression The most notable in vivo application of clone 22D1 is its ability to induce temporary knockdown of SIGNR1 expression when injected into mice. This functional blocking property makes it particularly valuable for studying the physiological roles of CD209b in immune responses. Neutralization Studies Clone 22D1 is commonly used for in vivo neutralization experiments to investigate CD209b's role in disease models. For example, in vivo neutralization of CD209b using this antibody has been shown to attenuate allergic airway inflammation in mice, with typical dosing at 100 μg per mouse. Functional Research ApplicationsThe antibody is employed to study biological pathways affected by the CD209b protein, including investigations into its role in:
The antibody's applications extend to neutralization assays, functional assays, and bioanalytical pharmacokinetic (PK) and anti-drug antibody (ADA) assays for studying CD209b-mediated biological processes. Commonly used antibodies or proteins that are co-used with 22D1 (anti-mouse CD209b/SIGN-R1) in the literature typically depend on the experimental context, but several patterns have emerged based on the common cell populations and immune pathways studied:
These combinations are typically used in flow cytometry, immunohistochemistry, and immunofluorescence to define specific splenic or lymph node macrophage subsets, to distinguish immune cell types, or in functional studies of innate immune pathways. In summary, the most commonly co-used antibodies or proteins with 22D1 include markers for macrophages (F4/80, CD68), myeloid cells (CD11b), B cells (CD19/B220), T cells (CD3/CD4/CD8), metallophilic macrophages (MOMA-1), TLR4/MD2, and select complement components—all depending on the specific cellular or functional context being explored. The key findings from scientific literature citing clone 22D1 primarily concern its use as a monoclonal antibody specific to mouse CD209b (SIGN-R1), a receptor involved in immune responses.
No citations directly associate "clone 22D1" with TSC22D1/TSC-22 proteins; most literature mentioning TSC22D1 refers instead to TGF-β stimulated clone-22, a gene family involved in cell differentiation and apoptosis, which is unrelated to the monoclonal antibody clone 22D1 used in immunology. In summary, clone 22D1 is a key tool for studying mouse CD209b (SIGN-R1) function, especially in the context of immunity and infectious disease models, with robust experimental backing for its specificity, utility, and protective effects. Based on the available information, specific dosing regimens for clone 22D1 are not documented in the current literature. The search results indicate that dosing information for this particular antibody clone across different mouse models has not been established or published. General Considerations for Antibody Dosing in Mouse ModelsWhile clone 22D1-specific data is unavailable, antibody dosing regimens in mouse models typically vary based on several factors: Target and Application: Different antibodies targeting various immune markers require distinct dosing strategies. For example, checkpoint blockade antibodies like anti-PD-1 typically use 200-500 μg per mouse, while anti-PD-L1 antibodies use 100-250 μg per mouse. Route of Administration: Most in vivo antibodies are administered via intraperitoneal injection, though some studies have explored intratumoral routes. Dosing Schedule: Common schedules include every 2-3 days or 2-3 times per week, depending on the antibody's half-life and the experimental goals. Model-Specific Variables: The specific mouse model, disease state (tumor models, infection models, autoimmune models), and whether the antibody is used as monotherapy or in combination therapy all influence optimal dosing regimens. If you are planning to use clone 22D1 (anti-mouse CD209b) in your research, you may need to consult directly with the antibody manufacturer or conduct preliminary dose-finding studies to establish an appropriate regimen for your specific experimental model. References & CitationsTechnical ProtocolsB  IHC FF   Certificate of Analysis |
Related Products
Prod No. | Description |
|---|---|
S211 | |
R1364 | |
I-140 | |
C247 | |
F1175 | |
S225 | |
A132 | |
S571 |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
